Induction of bone formation by activated monocytes / macrophages depends on Oncostatin M signaling
暂无分享,去创建一个
S. Chevalier | H. Gascan | D. Heymann | F. Blanchard | J. Delecrin | F. Redini | C. Richards | R. Brion | Y. Danger | Pierre J Guihard | E. David | B. Brounais
[1] D. Hume,et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[2] D. Magne,et al. TNF-α stimulates alkaline phosphatase and mineralization through PPARγ inhibition in human osteoblasts. , 2011, Bone.
[3] M. Feldmann,et al. TNF-α promotes fracture repair by augmenting the recruitment and differentiation of muscle-derived stromal cells , 2011, Proceedings of the National Academy of Sciences.
[4] S. Goodman,et al. Modulating osteogenesis of mesenchymal stem cells by modifying growth factor availability. , 2010, Cytokine.
[5] Hélène Rouard,et al. Clinical-grade production of human mesenchymal stromal cells: occurrence of aneuploidy without transformation. , 2010, Blood.
[6] T. Martin,et al. Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice. , 2010, The Journal of clinical investigation.
[7] P. Carmeliet,et al. Increased skeletal VEGF enhances β‐catenin activity and results in excessively ossified bones , 2010, The EMBO journal.
[8] N. Walsh,et al. Bone remodeling in rheumatic disease: a question of balance , 2010, Immunological reviews.
[9] E Choy,et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. , 2009, Autoimmunity reviews.
[10] J. Hamilton,et al. Proinflammatory cytokines inhibit osteogenic differentiation from stem cells: implications for bone repair during inflammation. , 2009, Osteoarthritis and cartilage.
[11] P. Tak,et al. The dynamics of macrophage lineage populations in inflammatory and autoimmune diseases. , 2009, Arthritis and rheumatism.
[12] D. Magne,et al. TNF-alpha and IL-1beta inhibit RUNX2 and collagen expression but increase alkaline phosphatase activity and mineralization in human mesenchymal stem cells. , 2009, Life sciences.
[13] M. Macoritto,et al. Autocrine Regulation of Interferon γ in Mesenchymal Stem Cells Plays a Role in Early Osteoblastogenesis , 2009, Stem cells.
[14] F. Blanchard,et al. The dual role of IL-6-type cytokines on bone remodeling and bone tumors. , 2009, Cytokine & growth factor reviews.
[15] S. Khosla,et al. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate , 2008, Proceedings of the National Academy of Sciences.
[16] D. Link,et al. Granulocyte Colony‐Stimulating Factor Induces Osteoblast Apoptosis and Inhibits Osteoblast Differentiation , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[17] J. Mege,et al. Macrophage Polarization in Bacterial Infections , 2008, The Journal of Immunology.
[18] David A. Hume,et al. Osteal Tissue Macrophages Are Intercalated throughout Human and Mouse Bone Lining Tissues and Regulate Osteoblast Function In Vitro and In Vivo1 , 2008, The Journal of Immunology.
[19] S. Chevalier,et al. Chronically Inflamed Human Tissues Are Infiltrated by Highly Differentiated Th17 Lymphocytes , 2008, The Journal of Immunology.
[20] Kunihiro Matsumoto,et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation , 2007, Nature Cell Biology.
[21] Nimrod Rozen,et al. Fracture repair: modulation of fracture-callus and mechanical properties by sequential application of IL-6 following PTH 1-34 or PTH 28-48. , 2007, Bone.
[22] Jae Hyun Kim,et al. Oncostatin M promotes osteogenesis and suppresses adipogenic differentiation of human adipose tissue‐derived mesenchymal stem cells , 2007, Journal of cellular biochemistry.
[23] S. Sa,et al. The Effects of IL-20 Subfamily Cytokines on Reconstituted Human Epidermis Suggest Potential Roles in Cutaneous Innate Defense and Pathogenic Adaptive Immunity in Psoriasis , 2007, The Journal of Immunology.
[24] A. Miyajima,et al. Oncostatin M Inhibits Adipogenesis through the RAS/ERK and STAT5 Signaling Pathways* , 2006, Journal of Biological Chemistry.
[25] K. Ishihara,et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. , 2006, Bone.
[26] C. Shin,et al. CCAAT/enhancer-binding protein delta activates the Runx2-mediated transcription of mouse osteocalcin II promoter. , 2006, Journal of molecular endocrinology.
[27] M. Malaise,et al. Interleukin-6: An osteotropic factor influencing bone formation? , 2005, Bone.
[28] A. Chott,et al. Interaction between Synovial Inflammatory Tissue and Bone Marrow in Rheumatoid Arthritis 1 , 2005, The Journal of Immunology.
[29] M. Neurath,et al. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer , 2005, Clinical reviews in allergy & immunology.
[30] S. Théoleyre,et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. , 2004, Cytokine & growth factor reviews.
[31] C. Colombeix,et al. Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKCδ and STAT3 , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[32] D. Rachmilewitz,et al. Interleukin 10-deficient mice develop osteopenia, decreased bone formation, and mechanical fragility of long bones. , 2004, Gastroenterology.
[33] R. Moots,et al. Secretion of oncostatin M by neutrophils in rheumatoid arthritis. , 2004, Arthritis and rheumatism.
[34] A. Munnich,et al. Null leukemia inhibitory factor receptor (LIFR) mutations in Stuve-Wiedemann/Schwartz-Jampel type 2 syndrome. , 2004, American journal of human genetics.
[35] L. Joosten,et al. Growth plate damage, a feature of juvenile idiopathic arthritis, can be induced by adenoviral gene transfer of oncostatin M: a comparative study in gene-deficient mice. , 2003, Arthritis and rheumatism.
[36] G. Lisignoli,et al. Human osteoblasts express functional CXC chemokine receptors 3 and 5: Activation by their ligands, CXCL10 and CXCL13, significantly induces alkaline phosphatase and β‐N‐acetylhexosaminidase release , 2003, Journal of cellular physiology.
[37] U. Lerner,et al. IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1 , 2002, The Journal of Immunology.
[38] H. Koyama,et al. Induction of Bone-Type Alkaline Phosphatase in Human Vascular Smooth Muscle Cells: Roles of Tumor Necrosis Factor-&agr; and Oncostatin M Derived From Macrophages , 2002, Circulation research.
[39] E. Benveniste,et al. Prostaglandin E2 Is a Novel Inducer of Oncostatin-M Expression in Macrophages and Microglia , 2002, The Journal of Neuroscience.
[40] F. Speleman,et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.
[41] E. Schwarz,et al. Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair. , 2002, The Journal of clinical investigation.
[42] Yoshiaki Ito,et al. Runt Domain Factor (Runx)-dependent Effects on CCAAT/ Enhancer-binding Protein δ Expression and Activity in Osteoblasts* , 2000, The Journal of Biological Chemistry.
[43] T. van der Poll,et al. Endotoxin down-regulates monocyte and granulocyte interleukin-6 receptors without influencing gp130 expression in humans. , 2000, The Journal of infectious diseases.
[44] M. Goldring,et al. The role of oncostatin M in animal and human connective tissue collagen turnover and its localization within the rheumatoid joint. , 1998, Arthritis and rheumatism.
[45] John R. Johnson,et al. The Effect of Postoperative Nonsteroidal Anti‐inflammatory Drug Administration on Spinal Fusion , 1998, Spine.
[46] T. Vischer,et al. Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. , 1997, The Journal of rheumatology.
[47] S. Chevalier,et al. Interleukin-6 Family of Cytokines Induced Activation of Different Functional Sites Expressed by gp130 Transducing Protein* , 1996, The Journal of Biological Chemistry.
[48] K Banovac,et al. Effect of Nonsteroidal Antiinflammatory Drugs on Fracture Healing: A Laboratory Study in Rats , 1995, Journal of orthopaedic trauma.
[49] C. Ware,et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. , 1995, Development.
[50] T. Libermann,et al. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide , 1994, Molecular and cellular biology.
[51] D. Heymann,et al. Direct anti-cancer effect of oncostatin M on chondrosarcoma , 2011 .
[52] S. Rantapää Dahlqvist,et al. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? , 2009, Clinical and experimental rheumatology.
[53] S. Kwan Tat,et al. IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. , 2004, Cytokine & growth factor reviews.
[54] J. Dewille,et al. Oncostatin M induces growth arrest of mammary epithelium via a CCAAT/enhancer-binding protein delta-dependent pathway. , 2002, Molecular cancer therapeutics.
[55] P. Roberson,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Activation of the Janus Kinase/STAT (Signal Transducer and Activator of Transcription) Signal Transduction Pathway by Interleukin-6-Type Cytokines Promotes , 2022 .
[56] E. Lubberts,et al. Adenoviral transfer of murine oncostatin M elicits periosteal bone apposition in knee joints of mice, despite synovial inflammation and up-regulated expression of interleukin-6 and receptor activator of nuclear factor-kappa B ligand. , 2002, The American journal of pathology.